Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?

We don't have comparative data that I am aware of. SWOG S0226 showed an improvement in PFS/OS for 1st line fulvestrant + anastrozole vs anastrozole, particularly for treatment-naive or > 10-year recurrent metastatic disease. Dr. @Dr. First Last (who led S0226) has opened a phase 2 trial using abemac...